• Home
  • Search Results
  • Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence.

Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence.

Cancer immunology, immunotherapy : CII (2015-01-27)
Marcin Okroj, Emelie Holmquist, Elise Nilsson, Lola Anagnostaki, Karin Jirström, Anna M Blom

Tumor cells often evade killing by the complement system by overexpressing membrane-bound complement inhibitors. However, production of soluble complement inhibitors in cells other than hepatocytes was rarely reported. We screened several breast cancer cell lines for expression of soluble complement inhibitor, complement factor I (FI). We also analyzed local production of FI in tissue microarrays with tumors from 130 breast cancer patients by in situ hybridization and immunohistochemistry. We found expression of FI in breast adenocarcinoma cell line MDA-MB-468 and confirmed its functional activity. Expression of FI at mRNA and protein levels was also confirmed in tumor cells and tumor stroma, both in fibroblasts and infiltrating immune cells. Multivariate Cox regression analyses revealed that high expression of FI protein in tumor cells was correlated with significantly shorter cancer-specific survival (HR 2.8; 95 % CI 1.0-7.5; p = 0.048) and recurrence-free survival (HR 3.4; 95 % CI 1.5-7.4; p = 0.002). High FI expression was positively correlated with tumor size (p < 0.001), and Nottingham histological grade (p = 0.015) and associated with estrogen and progesterone receptor status (p = 0.03 and p = 0.009, respectively). Our data show that FI is expressed in breast cancer and is associated with unfavorable clinical outcome.

Product Number
Product Description

MOPS, ≥99.5% (titration)
Trimesic acid, 95%
MOPS, BioPerformance Certified, suitable for cell culture, ≥99.5% (titration)
Trimethylaluminum, 97%
Trimethylaluminum solution, 2.0 M in toluene
MOPS, BioUltra, for molecular biology, ≥99.5% (T)
Trimethylaluminum, packaged for use in deposition systems
Trimethylaluminum solution, 2.0 M in hexanes
MOPS, BioXtra, ≥99.5% (titration)
Trimethylaluminum solution, 2.0 M in heptane
MOPS, anhydrous, free-flowing, Redi-Dri, ≥99.5%

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.